Irbesartan/Hidroclorotiazida Tarbis

Irbesartan, the active ingredient in Irbesartan/Hidroclorotiazida Tarbis, is an Angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with hydrochlorothiazide, and is indicated for adults who need blood pressure control.

GNH USA supplies Irbesartan/Hidroclorotiazida Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure and helps prevent cardiovascular complications. - Diabetic nephropathy: slows the progression of kidney damage associated with diabetes. - Stroke risk reduction: contributes to lowering the likelihood of stroke in patients with high blood pressure.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or weakness. - Increased urination. - Electrolyte disturbances such as low potassium. - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension. - Hyperkalemia. - Acute kidney injury. - Allergic reactions including rash or angioedema. - Pancreatitis. - Blood dyscrasias such as agranulocytosis.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly: ensure therapeutic response and avoid excessive drops. - Assess renal function: check serum creatinine and eGFR at baseline and periodically. - Check electrolytes: especially potassium and sodium levels. - Avoid use in pregnancy: drug is classified as Category D and may harm the fetus. - Use caution in elderly patients: increased sensitivity to blood‑pressure changes. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines. Review patient medication lists carefully.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can cause renal impairment. - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia. - Lithium: may increase lithium concentrations and toxicity. - Dual ACE inhibitor/ARB therapy: heightened risk of hypotension and kidney injury.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect. - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustments. - CYP3A4 inhibitors (e.g., itraconazole): can raise irbesartan levels. - Diuretics that affect electrolytes: monitor potassium and sodium balance.